Immune Therapeutics
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2431 Aloma Ave Ste 124, Winter Park, Flo...Phone Number
(888) 613-8802Website
www.immunetherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Immune Therapeutics
Founded in 1993, headquartered in Winter Park, Florida, Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of the company's highly innovative immunotherapies. IMUN is a biotechnology company developing T-Activation immunotherapies to achieve immunomodulation in patients with autoimmune and inflammatory disease and cancer and infectious diseases.Explore more
Immune Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Immune Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Immune Therapeutics is spiking on competitors!
Check if Immune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Immune Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Immune Therapeutics has new funding data
Immune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Immune Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Immune Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Immune Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Immune Therapeutics
Compare insights from companies similar to Immune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immune Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immune Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immune Therapeutics.
Immune Therapeutics financials insights
Gather financial insights about Immune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$1.5M
Immune Therapeutics Tech Stack
A closer look at the technologies used by Immune Therapeutics
Most Recent Scoops
Executive Move
Board of Directors
Left Company
Executive Move
Open Position
Executive Move
Promotion
Executive Move
Kelly Wilson, Chief Operating Officer, has assumed the role of Interim Chief Executive Officer & Interim President. Wilson will step down from these roles once a successor has been found.
Lateral Move
Executive Move
Immune Therapeutics News & Media
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes
ORLANDO, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce it is in full compliance with OTC Markets following the filing of its 10-Q allowing removal of the delinquency flag and a return to Current Information status with the OTImmune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Glen Farmer as Chief Financial Officer and Kelly Wilson as Chief Operating Officer. Mr. Farmer will be replacing Dr. Stephen Wilson who was serving as tImmune Therapeutics, Inc. Announces Expansion of its Board of Directors
ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced that it will expand its Board of Directors from two to five members.Immune Therapeutics Announces Restructuring Plan
Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immune Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 1993, headquartered in Winter Park, Florida, Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of the company's highly innovative immunotherapies. IMUN is a biotechnology company developing T-Activation immunotherapies to achieve immunomodulation in patients... Read More
